Ho Hee Hwa, Er Ching Min, Ong Paul Jau Lueng, Ooi Yau Wei
Department of Cardiology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore,
Heart Vessels. 2015 Jul;30(4):545-8. doi: 10.1007/s00380-014-0513-8. Epub 2014 Apr 23.
Drug-eluting bioresorbable vascular scaffold (BVS) is a revolutionary treatment option for obstructive coronary artery disease in percutaneous coronary intervention. It restores blood flow to the myocardium but unlike permanent metallic stent, BVS dissolves in the body within 2 years. This allows the coronary vessel to regain its normal function and motion. The clinical efficacy and safety of BVS in the first-in-human trials have been reported with low major adverse cardiac event rates observed at short- and long-term follow-up. The incidence of BVS scaffold thrombosis (ST) in these studies was 0 %. There is limited data on the incidence of BVS ST in the real world. We report 2 cases of subacute ST involving BVS in our real-world practice and discuss on the possible mechanisms of these thrombotic episodes (with insights from intracoronary imaging studies).
药物洗脱生物可吸收血管支架（BVS）是经皮冠状动脉介入治疗中阻塞性冠状动脉疾病的一种革命性治疗选择。它可恢复心肌血流，但与永久性金属支架不同，BVS在2年内可在体内溶解。这使得冠状动脉能够恢复其正常功能和运动。在首次人体试验中，BVS的临床疗效和安全性已被报道，在短期和长期随访中观察到较低的主要不良心脏事件发生率。这些研究中BVS支架血栓形成（ST）的发生率为0%。关于现实世界中BVS ST发生率的数据有限。我们报告了在我们的现实世界实践中2例涉及BVS的亚急性ST病例，并讨论了这些血栓形成事件的可能机制（结合冠状动脉内成像研究的见解）。
